Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- COTY +5.9% (guidance), SCS +3.3%, GIS +0.5%
Other news:
- EXAI +27.3% (announces AI drug discovery collaboration with Merck KGaA)
- CATC +20.9% (CATC to merge with EBC)
- PBYI +14.4% (treatment of small cell lung cancer (alisertib) granted orphan designation yesterday)
- ATRA +8.2% (to submit Tab-cel BLA in Q2 following FDA agreement on comparability)
- UXIN +4.9% (announces RMB1.5 bln equity investment in its Hefei Subsidiary)
- HAIN +4% (CEO bought 10000 shares)
- NNDM +4% (receives approval from Israeli court to resume share repurchase plan)
- TMCI +3.9% (Highlights New Product Innovations and Updated ALIGN3D™
- Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023)
- DNMR +3.8% (expanding its collaboration with Chevron (CVX) Phillips Chemical)
- PINS +3.7% (authorizes $1 bln stock repurchase program)
- SWBI +3.1% (authorizes $50 million stock repurchase program through September 19 2024)
- NIO +2.7% (prices offering of $500 mln of convertible senior notes due 2029 and $500 mln of convertible senior notes due 2030)
- SPIR +2.1% (awarded a $2.8 million 12-month contract by the National Oceanic and Atmospheric Administration for satellite weather data)
- AZN +1.6% (Alexion completes Pfizer (PFE) gene therapy agreement)
- TRTN +1.5% (BIP receives all regulatory approvals to complete TRTN acquisition)
- AGX +1.3% (increases dividend)
- SLVM +1.3% (increases regular dividend by 20%; also declares special dividend of $0.30/sh)
- MSGE +1.3% (prices secondary offering of 7.15 shares of common stock at $32.50 per share)
- ALVO +1.1% (provides U.S. regulatory update on AVT02)
Analyst comments:
- HPP +3.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- AZUL +2.5% (upgraded to Buy from Neutral at Goldman)
- WING +1.5% (upgraded to Outperform from Neutral at Wedbush)